Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease
Article first published online: 7 DEC 2006
©2006 The Author(s)/Journal Compilation © 2006 Foundation Acta Pædiatrica/Acta Pædiatrica
Volume 96, Issue 1, pages 128–130, January 2007
How to Cite
Kolho, K.-L., Ruuska, T. and Savilahti, E. (2007), Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatrica, 96: 128–130. doi: 10.1111/j.1651-2227.2007.00042.x
- Issue published online: 20 DEC 2006
- Article first published online: 7 DEC 2006
- Received 15 May 2006; revised 30 June 2006; accepted 11 July 2006
- Adverse effect;
- Crohn´s disease;
- TNF-alpha antagonist;
- Ulcerative colitis
Since 2000 we have introduced 141 Infliximab infusions to 23 children with severe inflammatory bowel disease. A total of seven severe adverse reactions occurred in 26% (6 of 23) of the children. Four reactions were acute (anaphylaxis n = 2; allergic reaction n = 2) and 3/4 of these children were younger than 10 years of age. Two children developed an abscess and one child had septicaemia and brain lesions related to progressive multifocal leucoencephalopathy.
Conclusion: adverse reactions to Infliximab infusions are common. Young children seem to be prone to severe allergic reactions although they are on azathioprine and conventional glucocorticoid therapy.